Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2005
09/01/2005US20050192243 Neuromuscular blocking agents and antagonists thereof
09/01/2005US20050192235 Compositions and methods for treating or preventing diseases of body passageways
09/01/2005US20050192225 Methods for treating Parkinson's disease
09/01/2005US20050192220 Potentiating activity of drug which affects central nervous system by systemically administrating the drug together with a compound which stimulates peripheral chemoreceptors of vagal afferents and, optionally, with stimulator of peripheral osmoreceptors of vagal afferents; analgesics, antidepressants
09/01/2005US20050192218 For producing analgesia in a mammalian subject
09/01/2005US20050192197 Peroxyoctanoic acid, octanoic acid, surfactants, carrier, and solubilizer, oxidizers; can be readily made, and can exhibit reduced odor; microbiocide
09/01/2005US20050191695 Documentation means for repertoires of NKR immunoreceptors and/or activatory or non-inhibitory immunoreceptor counterparts of NKR immunoreceptors
09/01/2005US20050191690 Membrane proteins for identifying modulators for prevention and treatment of infection, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders
09/01/2005US20050191670 High throughput chemical handling system
09/01/2005US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders
09/01/2005US20050191621 CD4-independent HIV envelope proteins as vaccines and therapeutics
09/01/2005US20050191375 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
09/01/2005US20050191368 for administration to male for treating or preventing prostate disease and/or vascular disease, the active components including saw palmetto, vitamin E, selenium, lycopene, zinc, vitamin B12, vitamin B6 and folic acid
09/01/2005US20050191367 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors
09/01/2005US20050191364 Use of enhanced water to improve blood sugar management
09/01/2005US20050191354 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
09/01/2005US20050191345 Temperature-sensitive liposomal formulation
09/01/2005US20050191342 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
09/01/2005US20050191323 Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof
09/01/2005US20050191301 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
09/01/2005US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells
09/01/2005US20050191288 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient
09/01/2005US20050191286 Activated growth factors, platelet ghost, plasma, white blood cells with optional antioxidant of vitamin A and/or C and/or E, and/or antibiotics and/or GHK-Cu
09/01/2005US20050191280 Immune regulation
09/01/2005US20050191276 Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase
09/01/2005US20050191275 Method for short-term and long-term drug dosimetry
09/01/2005US20050191244 Abuse-resistant pharmaceutical dosage form
09/01/2005US20050191241 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
09/01/2005CA2558475A1 Antimicrobial formulations and methods of using the same
09/01/2005CA2557158A1 Prophylactic antimigraine agents
09/01/2005CA2557154A1 Anticancer agent containing bl-angiostatin
09/01/2005CA2556870A1 Dopamine-agonist combination therapy for improving sleep quality
09/01/2005CA2556160A1 Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
09/01/2005CA2555421A1 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
09/01/2005CA2555386A1 Use of cholinesterase inhibitors for treating vascular depression
09/01/2005CA2555261A1 Management of ophthalmologic disorders, including macular degeneration
09/01/2005CA2554040A1 Use of meloxicam for the treatment of respiratory diseases in pigs
09/01/2005CA2553367A1 Composition for treating a dermatological inflammatory response and method of preparation thereof
09/01/2005CA2552939A1 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins
09/01/2005CA2552903A1 Pharmaceutical compositions based on anticholinergics and pegsunercept
09/01/2005CA2551787A1 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent
08/2005
08/31/2005EP1568382A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER
08/31/2005EP1568381A1 Remedy for hormone-dependent cancer
08/31/2005EP1568376A2 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
08/31/2005EP1568369A1 Use of meloxicam for the treatment of respiratory diseases in pigs
08/31/2005EP1568368A1 Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
08/31/2005EP1567663A2 Molecular determinants of myeloma bone disease and uses thereof
08/31/2005EP1567644A2 Tissue specific genes and gene clusters
08/31/2005EP1567198A2 Materials and methods for treating ocular-related disorders
08/31/2005EP1567182A2 Preventing desensitization of receptors
08/31/2005EP1567180A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism
08/31/2005EP1567179A1 Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
08/31/2005EP1567174A2 Compositions for diabetes treatment and prophylaxis
08/31/2005EP1567170A2 Use of beta-glucans against biological warfare weapons and pathogens including anthrax
08/31/2005EP1567163A2 Method of treating nausea, vomiting, retching or any combination thereof
08/31/2005EP1567158A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
08/31/2005EP1567157A1 Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases
08/31/2005EP1567154A2 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
08/31/2005EP1567149A2 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
08/31/2005EP1567127A2 Method of modifying the release profile of sustained release compositions
08/31/2005EP1567113A2 Antifungal formulations
08/31/2005EP1567101A2 Prophylactic treatment methods
08/31/2005EP1567014A2 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
08/31/2005EP1492548B1 Composition for the topical treatment of vulvovaginitis and mycoses
08/31/2005EP1461063A4 Treatment of glioblastoma with thymosin-alpha 1
08/31/2005EP1401407B1 Porous sponge-like cellulosic material for treatment of injuries
08/31/2005EP1397359B1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
08/31/2005EP1392288B1 Medicament containing an effector of the glutathione metabolism (ampbroxol) together with alpha-lipoic acid for treating diabetes mellitus
08/31/2005EP1330257B1 Gnrh analogues for treatment of urinary incontinence
08/31/2005EP1240168B1 Bicyclic inhibitors of glycogen synthase kinase 3
08/31/2005EP1230925B1 Use of a trifluridine derivative alone or combined with a thymidine phosphorylase inhibitor for the treatment of hiv
08/31/2005EP1169060B1 Sodium channel blocker compositions and the use thereof
08/31/2005EP1095020B1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them
08/31/2005EP1035833B1 Compositions for nasal administration
08/31/2005EP0973819B1 Non-antigenic branched polymer conjugates
08/31/2005CN1662664A Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
08/31/2005CN1662663A DNA enzyme to inhibit plasminogen activator inhibitor-1
08/31/2005CN1662661A Method for detecting increased susceptibility to tumours
08/31/2005CN1662647A Plant thymidine kinases and their use
08/31/2005CN1662548A Regeneration of endogenous myocardial tissue by induction of neovascularization
08/31/2005CN1662544A Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
08/31/2005CN1662524A Indole derivatives useful as histamine h3 antagonists
08/31/2005CN1662514A Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
08/31/2005CN1662508A Compounds, compositions and methods
08/31/2005CN1662506A Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
08/31/2005CN1662502A Cyanoguanidine produgs
08/31/2005CN1662501A Cyanoguanidine prodrugs
08/31/2005CN1662498A Novel tetrahydropyridine derivatives as renin inhibitors
08/31/2005CN1662496A Cannabinoid receptor agonists
08/31/2005CN1662495A Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
08/31/2005CN1662493A Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
08/31/2005CN1662257A Combination of PDE5 inhibitors with angiotensin II receptor antagonists
08/31/2005CN1662256A Combination of angiotensin II receptor blocker and beta-blocker for secondary prevention of myocardial infarction
08/31/2005CN1662255A Use of substances for treating tumors
08/31/2005CN1662254A ALCAM and ALCAM modulators
08/31/2005CN1662252A Acidic insulin preparations with improved stability
08/31/2005CN1662251A Adjuvant enhanced immunotherapy
08/31/2005CN1662249A Osteopontin, oligodendrocytes and myelination
08/31/2005CN1662246A Combination therapy wherein a serotonin reuptake inhibitor is used
08/31/2005CN1662241A Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
1 ... 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 ... 1151